^
    Back
    Association details:
    Biomarker:IKZF1 deletion
    Cancer:Acute Myelogenous Leukemia
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

    Published date:
    11/04/2020
    Excerpt:
    Cases harboring Ik2 subtype deletion or Ik6 subtype deletion showed significantly worse EFS (hazard ratio [HR] = 1.91; p = 0.048) and OS (HR = 2.36; p = 0.019) than non-IKZF1 deletion cases or cases with IKZF1 deletion other than Ik2 or Ik6 subtype
    Secondary therapy:
    cyclophosphamide + vincristine + dexamethasone + SA033
    DOI:
    10.1182/blood-2020-136676